You are now leaving the Kedrion Corporate site. The information available in your chosen website may not be in compliance with EU legislation regulating the advertising of medicinal products for human use, nor do the opinions expressed necessarily reflect the Company’s positions or are endorsed by it.
NO
YES
BACK TO ALL NEWS/

21-12-2018

Closing of antitrust investigation

Released: 21.12.2018 - 17.28 GMT
RNS Number: 3510L
Kedrion in S.p.A.
 

Castelvecchio Pascoli (Lucca, Italy), 21 December 2018 – Kedrion announces that today, 21 December 2018, the Company has been notified of the closing of the investigation opened by the Italian antitrust authority “Autorità Garante della Concorrenza e del Mercato” (AGCM) for a potential anticompetitive conduct by Kedrion S.p.A. and Grifols Italia S.p.A.

The authority has determined that the joint participation of Kedrion and Grifols Italia through a temporary consortium (“Raggruppamento Temporaneo di Imprese”) in the tender organised by the Regional agency Intercent-ER on behalf of a grouping of regions led by Emilia Romagna and awarded to the consortium Kedrion-Grifols in September 2017 did not harm competition. Therefore the AGCM has dismissed the case with no enforcement of sanctions as no violation of the competition rules was found.

The proceeding initiated on January 10th 2018 in accordance with Article 2 of the Italian law n. 287/1990 and Article 101 of the Treaty on the Functioning of the European Union following a complaint filed with the antitrust authority by two other companies that also participated in the tender (Baxter-Shire and CSL Behring).

About Kedrion

Kedrion is a leading biopharmaceutical company that specializes in the development, production and distribution of plasma-derived therapeutic products for use in treating serious diseases, disorders and conditions such as immune system deficiencies and coagulation disorders.

The Company operates through a fully integrated business model from the collection of plasma in its own centers in the United States, Hungary and Germany to fractionation and production in its manufacturing facilities located in Italy, Hungary and the United States.

Headquartered in Castelvecchio Pascoli (Italy), Kedrion has over 2,500 employees and a commercial presence in approximately 100 countries worldwide.

Kedrion places a high value on the welfare of those who benefit from its products, as well as on the people and the communities it serves.

Additional information about Kedrion can be found at kedrion.com

For more information please contact: investor@kedrion.com